Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal · people with CIDP
Interferon beta‐1a showed no clear difference in participants who completed the study and did not restart IVIg… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
At least 30% reduction in pain · adults with neuropathic pain
1 finding from 1 review
At least 50% reduction in pain · adults with neuropathic pain
Tramadol may leads to higher at least 50% reduction in pain compared with placebo (low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · adults with neuropathic pain
1 finding from 1 review
Withdrawals due to adverse events · adults with neuropathic pain
Tramadol may leads to higher withdrawal due to adverse event compared with placebo (low certainty).
1 finding from 1 review
Number experiencing adverse effects · adults with neuropathic pain
Tramadol may leads to higher participants experiencing any adverse event compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Death · adults with neuropathic pain
1 finding from 1 review
Survival · people with ALS
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · people with ALS
1 finding from 1 review
Quality of Life: SF‐36 (physical component) · people with ALS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SAQLI) · people with ALS
1 finding from 1 review
Adverse events (not reported) · people with ALS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Survival at 1 year Estimated survival at 1 year based on trials of 6 and 9 months' duration · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline in MVIC Expressed as arm megascore1 · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline of % predicted FVC · people with ALS/MND
1 finding from 1 review